OS Therapies grants CEO 900,000 options at $1.25

The options vest in 12 equal monthly installments, conditional on continued employment on each vesting date.

Available on EDGAR 10/30/2026 - 09:00 PM EDT Accepted by SEC EDGAR 10/30/2026 - 08:59 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

OS Therapies Inc (OSTX) granted President and CEO Paul A. Romness options to purchase 900,000 common shares on October 22, 2026, at an exercise price of $1.25 per share. The options expire October 22, 2036, and vest in 12 equal monthly installments, provided Romness remains an employee on each applicable vesting date. The filing also reports that he directly held 2,473,000 common shares.

Insider Trade Summary

Grant/Award: 900,000 shares

Grant/Award 1 txn

Insider Romness Paul A.

Role President and CEO

Type	Security	Shares	Price	Value
Grant/Award	Stock options (right to buy) F1	900,000	$0.00	$0.00
Holding	Common Stock	--	--	--

Holdings After Transaction: Stock options (right to buy) — 900,000 contracts (Direct); Common Stock — 2,473,000 shares (Direct)

Footnotes (1)

1. F1. On October 22, 2026, the reporting person was granted options to purchase 900,000 shares of the issuer's common stock pursuant to the terms and conditions of a stock option award agreement and the issuer's amended and restated 2023 incentive compensation plan. These options vest in 12 equal installments on each monthly anniversary of the date of grant, provided that the reporting person is serving as an employee of the issuer on each applicable vesting date.

Key Figures

Options granted: 900,000 options to purchase common shares Exercise price: $1.25 per share Vesting installments: 12 equal monthly installments +2 more

5 metrics

Options granted 900,000 options to purchase common shares Granted October 22, 2026

Exercise price $1.25 per share Options granted October 22, 2026

Vesting installments 12 equal monthly installments Subject to continued employment on each applicable vesting date

Expiration date October 22, 2036 Options granted October 22, 2026

Direct common shares held 2,473,000 common shares Reported October 22, 2026

Key Terms

exercise price, stock option award agreement, incentive compensation plan

3 terms

exercise price financial

"at an exercise price of $1.25 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

stock option award agreement financial

"terms and conditions of a stock option award agreement"

A stock option award agreement is a legal document that gives a person the right to buy a company’s shares at a fixed price later, with clear rules about when those rights become usable, how long they last, and any conditions for exercising them. For investors it matters because these agreements can increase the total shares outstanding and affect company costs and incentives—like a coupon that can turn into new stock, changing ownership and future stock supply.

incentive compensation plan financial

"issuer's amended and restated 2023 incentive compensation plan"

An incentive compensation plan is a formal program that rewards employees and executives with bonuses, stock, or other payments tied to specific performance goals—such as revenue, profit, productivity, or long‑term share price. Investors watch these plans because they shape how leaders make decisions and take risks; like paying a coach by wins rather than effort, well‑designed plans can drive sustainable growth while poor designs can encourage short‑term behaviors that harm shareholder value.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many options did OSTX's CEO receive, and what are their terms?

Paul A. Romness, OS Therapies Inc's President and CEO, received options to purchase 900,000 common shares at an exercise price of $1.25 per share. They expire October 22, 2036, and vest in 12 equal monthly installments while he remains an employee on each vesting date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Romness Paul A.

(Last) (First) (Middle)

C/O OS THERAPIES INCORPORATED

115 PULLMAN CROSSING ROAD, SUITE 103

(Street)

GRASONVILLE MARYLAND 21638

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
OS Therapies Inc [ OSTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/22/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock								2,473,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock options (right to buy)	$1.25	10/22/2026		A		900,000		(1)	10/22/2036	Common Stock	900,000	$0	900,000	D

Explanation of Responses:

1. On October 22, 2026, the reporting person was granted options to purchase 900,000 shares of the issuer's common stock pursuant to the terms and conditions of a stock option award agreement and the issuer's amended and restated 2023 incentive compensation plan. These options vest in 12 equal installments on each monthly anniversary of the date of grant, provided that the reporting person is serving as an employee of the issuer on each applicable vesting date.

	/s/ Paul A. Romness	10/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)